Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Carla Torre, José Guerreiro, Patrícia Longo, João Filipe Raposo, Hubert Leufkens & Ana Paula Martins. (2018) Effect of different methods for estimating persistence and adherence to new glucose-lowering drugs: results of an observational, inception cohort study in Portugal. Patient Preference and Adherence 12, pages 1471-1482.
Read now
Read now
Francesco Giorgino, Alfred Penfornis, Valeria Pechtner, Raffaella Gentilella & Antonella Corcos. (2018) Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. Patient Preference and Adherence 12, pages 707-719.
Read now
Read now
Lawrence Blonde, Charmi Patel, Brahim Bookhart, Michael Pfeifer, Yen-Wen Chen & Bingcao Wu. (2018) A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin. Current Medical Research and Opinion 34:6, pages 1143-1152.
Read now
Read now
Carol H. Wysham, Dominic Pilon, Mike Ingham, Marie-Hélène Lafeuille, Bruno Emond, Rhiannon Kamstra, Michael Pfeifer & Patrick Lefebvre. (2018) Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. Current Medical Research and Opinion 34:6, pages 1125-1133.
Read now
Read now
Articles from other publishers (24)
Wajd Alkabbani, Baiju R. Shah, Arsène Zongo, Dean T. Eurich, Mhd Wasem Alsabbagh & John‐Michael Gamble. (2023) Post‐initiation predictors of discontinuation of the sodium‐glucose cotransporter‐2 inhibitors: A comparative cohort study from the United Kingdom. Diabetes, Obesity and Metabolism 25:12, pages 3490-3500.
Crossref
Crossref
Eugenia Piragine, Davide Petri, Alma Martelli, Vincenzo Calderone & Ersilia Lucenteforte. (2023) Adherence to Oral Antidiabetic Drugs in Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis. Journal of Clinical Medicine 12:5, pages 1981.
Crossref
Crossref
Hitoshi Watanabe, Wen Du, Jinsook Son, Lina SuiShun-ichiro Asahara, Irwin J. Kurland, Taiyi Kuo, Takumi Kitamoto, Yasutaka Miyachi, Rafael de Cabo & Domenico Accili. (2023) Cyb5r3-based mechanism and reversal of secondary failure to sulfonylurea in diabetes. Science Translational Medicine 15:681.
Crossref
Crossref
Domenico Accili, Wen Du, Takumi Kitamoto, Taiyi Kuo, Wendy McKimpson, Yasutaka Miyachi, Maria Mukhanova, Jinsook Son, Liheng Wang & Hitoshi Watanabe. (2022) Reflections on the state of diabetes research and prospects for treatment. Diabetology International 14:1, pages 21-31.
Crossref
Crossref
Reema Mody, Janna Manjelievskaia, Elizabeth H. Marchlewicz, Raleigh E. Malik, Nicole M. Zimmerman, Debra E. Irwin & Maria Yu. (2022) Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice. Clinical Therapeutics 44:4, pages 537-554.
Crossref
Crossref
Federico Rea, Stefano Ciardullo, Laura Savaré, Gianluca Perseghin & Giovanni Corrao. (2021) Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting. Diabetes Research and Clinical Practice 180, pages 109035.
Crossref
Crossref
Erin R. Weeda, Alyssa K. Muraoka, Matthew D. Brock & Jessica M. Cannon. (2021) Medication adherence to injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta‐analysis. International Journal of Clinical Practice 75:9.
Crossref
Crossref
Bogdan Vlacho, Manel Mata-Cases, Xavier Mundet-Tudurí, Joan-Antoni Vallès-Callol, Jordi Real, Magi Farre, Xavier Cos, Kamlesh Khunti, Dídac Mauricio & Josep Franch-Nadal. (2021) Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study. Frontiers in Endocrinology 12.
Crossref
Crossref
Sara Denicolò, Paul Perco, Stefanie Thöni & Gert Mayer. (2021) Non-adherence to antidiabetic and cardiovascular drugs in type 2 diabetes mellitus and its association with renal and cardiovascular outcomes: A narrative review. Journal of Diabetes and its Complications 35:7, pages 107931.
Crossref
Crossref
Ann‐Marie Svensson, Anders Toll, Jeremie Lebrec, Mervete Miftaraj, Stefan Franzén & Björn Eliasson. (2020) Treatment persistence in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonists in clinical practice in Sweden. Diabetes, Obesity and Metabolism 23:3, pages 720-729.
Crossref
Crossref
Lawrence Blonde, Charmi Patel, Bingcao Wu, Yen-Wen Chen, Christopher D. Pericone & Brahim Bookhart. (2020) Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States. Advances in Therapy 38:1, pages 594-606.
Crossref
Crossref
Richard Ofori‐Asenso, Berhe W. Sahle, Ken Lee Chin, Mohsen Mazidi, Zanfina Ademi, Marie Louise De Bruin & Danny Liew. (2020) Poor adherence and persistence to sodium glucose co‐transporter 2 inhibitors in real‐world settings: Evidence from a systematic review and meta‐analysis. Diabetes/Metabolism Research and Reviews 37:1.
Crossref
Crossref
Richard Ofori-Asenso, Jenni Ilomaki, K.L. Chin, Mohsen Mazidi, Ella Zomer, J.S. Bell, Dianna J. Magliano & Danny Liew. (2019) Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study. Diabetes Research and Clinical Practice 158, pages 107909.
Crossref
Crossref
B. Guerci, B. Charbonnel, P. Gourdy, S. Hadjadj, H. Hanaire, M. Marre & B. Vergès. (2019) Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings. Diabetes & Metabolism 45:6, pages 528-535.
Crossref
Crossref
Mukul Singhal, Hiangkiat Tan, Craig I Coleman, Michelle Han, Chi Nguyen & Michael Ingham. (2019) Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA. BMJ Open Diabetes Research & Care 7:1, pages e000704.
Crossref
Crossref
Richard Ofori-Asenso, Danny Liew, Samanta Lalic, Mohsen Mazidi, Dianna J. Magliano, Zanfina Ademi, J. Simon Bell & Jenni Ilomaki. (2019) Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study. Advances in Therapy 36:11, pages 3265-3278.
Crossref
Crossref
Craig I Coleman, Shivani Pandya, Li Wang, Onur Baser, Jennifer Cai, Mike Ingham & Brahim Bookhart. (2019) Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients. Journal of Comparative Effectiveness Research 8:11, pages 889-905.
Crossref
Crossref
Gian Paolo Fadini, Bendetta Maria Bonora, Annunziata Lapolla, Bruno Fattor, Paola Silvia Morpurgo, Natalino Simioni & Angelo Avogaro. (2019) Comparative effectiveness of exenatide once‐weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta‐analysis of observational studies. Diabetes, Obesity and Metabolism 21:5, pages 1255-1260.
Crossref
Crossref
Reema Mody, Qing Huang, Maria Yu, Ruizhi Zhao, Hiren Patel, Michael Grabner & Laura Fernández Landó. (2019) Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States. Diabetes, Obesity and Metabolism 21:4, pages 920-929.
Crossref
Crossref
G. Reach, M. Pellan, A. Crine, C. Touboul, A. Ciocca & Y. Djoudi. (2018) Holistic psychosocial determinants of adherence to medication in people with type 2 diabetes. Diabetes & Metabolism 44:6, pages 500-507.
Crossref
Crossref
S. Halimi. (2018) Diabète de type 2 : observance thérapeutique aux nouveaux antidiabétiques. Médecine des Maladies Métaboliques 12:6, pages 487-495.
Crossref
Crossref
Jennifer Cai, Linda M. Delahanty, Sydney Akapame, April Slee & Shana Traina. (2018) Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials. The Patient - Patient-Centered Outcomes Research 11:3, pages 341-352.
Crossref
Crossref
Carol H. Wysham, Dominic Pilon, Mike Ingham, Marie -Hélène Lafeuille, Bruno Emond, Rhiannon Kamstra, Michael Pfeifer & Patrick Lefebvre. (2018) Hba1C Control And Cost-Effectiveness in Patients With Type 2 Diabetes Mellitus Initiated On Canagliflozin or A Glucagon-Like Peptide 1 Receptor Agonist in A Real-World Setting. Endocrine Practice 24:3, pages 273-288.
Crossref
Crossref
Erin K. Buysman, Amy Anderson, Shaffeeulah Bacchus & Mike Ingham. (2017) Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin. Advances in Therapy 34:4, pages 937-953.
Crossref
Crossref